Production and Application of CAR T Cells: Current and Future Role of Europe.
CAR T cells
automation
cancer treatment
manufacturing
regulation
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
05
2021
accepted:
23
07
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
8
9
2021
Statut:
epublish
Résumé
Rapid developments in the field of CAR T cells offer important new opportunities while at the same time increasing numbers of patients pose major challenges. This review is summarizing on the one hand the state of the art in CAR T cell trials with a unique perspective on the role that Europe is playing. On the other hand, an overview of reproducible processing techniques is presented, from manual or semi-automated up to fully automated manufacturing of clinical-grade CAR T cells. Besides regulatory requirements, an outlook is given in the direction of digitally controlled automated manufacturing in order to lower cost and complexity and to address CAR T cell products for a greater number of patients and a variety of malignant diseases.
Identifiants
pubmed: 34490302
doi: 10.3389/fmed.2021.713401
pmc: PMC8418055
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
713401Informations de copyright
Copyright © 2021 Vucinic, Quaiser, Lückemeier, Fricke, Platzbecker and Koehl.
Déclaration de conflit d'intérêts
AQ and PL declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. VV discloses honoraria for Novartis, Gilead, BMS, and travel grants from Gilead. SF states honorary activities for Novartis. With regard to the production of cell therapeutics, there are cooperations with the companies Novartis and Miltenyi Biotec. UP discloses consulting and fee for service activities for Novartis, Gilead and BMS. UK states that she is a consultant in immuno-oncology for AstraZeneca, Affimed, Glycostem, GammaDelta and Zelluna, and that she has collaborations with Novartis and Miltenyi Biotec regarding the production of CAR-T cells.
Références
Methods Mol Biol. 2020;2086:151-163
pubmed: 31707674
Clin J Oncol Nurs. 2007 Feb;11(1 Suppl):37-42
pubmed: 17471824
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Eur J Immunol. 2021 Sep;51(9):2151-2163
pubmed: 34196410
Cancers (Basel). 2020 Sep 09;12(9):
pubmed: 32916883
EMBO Mol Med. 2017 Sep;9(9):1183-1197
pubmed: 28765140
Cancer Immunol Immunother. 2012 Aug;61(8):1269-77
pubmed: 22274776
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
Curr Opin Chem Biol. 2013 Jun;17(3):385-92
pubmed: 23623807
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Hum Gene Ther. 2017 Nov;28(11):1047-1060
pubmed: 28810803
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
Biotechnol J. 2018 Feb;13(2):
pubmed: 28840981
Cancer Discov. 2017 Oct;7(10):OF1
pubmed: 28887358
Cytotherapy. 2017 Apr;19(4):531-542
pubmed: 28131632
Cytotherapy. 2018 Mar;20(3):394-406
pubmed: 29287970
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Transfus Med Hemother. 2019 Feb;46(1):47-54
pubmed: 31244581
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Sci Transl Med. 2011 Aug 10;3(95):95ra73
pubmed: 21832238
Front Immunol. 2020 Mar 20;11:482
pubmed: 32528460
Front Med (Lausanne). 2018 May 23;5:150
pubmed: 29876351
Drug Des Devel Ther. 2018 Oct 05;12:3343-3356
pubmed: 30323566
Cancer Gene Ther. 2015 Mar;22(2):72-8
pubmed: 25613483
Trends Biotechnol. 2020 Oct;38(10):1099-1112
pubmed: 31982150
Biotechnol J. 2020 Sep;15(9):e2000177
pubmed: 32592336
Cancer Discov. 2018 Jan;8(1):5-6
pubmed: 29113977
Cytotherapy. 2020 Feb;22(2):57-69
pubmed: 32014447
Curr Opin Hematol. 2015 Nov;22(6):476-83
pubmed: 26457960
Hum Gene Ther. 2016 Oct;27(10):860-869
pubmed: 27562135
J Immunol. 1998 Sep 15;161(6):2791-7
pubmed: 9743337
Sci Rep. 2019 Jul 23;9(1):10634
pubmed: 31337787
Curr Hematol Malig Rep. 2019 Aug;14(4):278-285
pubmed: 31254154
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Lancet Oncol. 2015 Jan;16(1):57-66
pubmed: 25524800
Cytotherapy. 2019 Mar;21(3):327-340
pubmed: 30685216
Oncotarget. 2017 Dec 21;9(7):7487-7500
pubmed: 29484126
Biol Blood Marrow Transplant. 2018 Jun;24(6):1243-1249
pubmed: 29421292
Recent Results Cancer Res. 2016;209:37-50
pubmed: 28101686
Curr Opin Biotechnol. 2018 Oct;53:164-181
pubmed: 29462761
Blood. 1995 Sep 1;86(5):2041-50
pubmed: 7655033
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33335028
Bull Cancer. 2019 Jan;106(1S):S102-S109
pubmed: 30661749
Biotechnol Lett. 2019 Nov;41(11):1245-1253
pubmed: 31541330
Hum Gene Ther. 2017 Oct;28(10):914-925
pubmed: 28847167
Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066
pubmed: 29605883
J Clin Oncol. 1998 Aug;16(8):2825-33
pubmed: 9704735
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
pubmed: 8421711
Blood. 1990 Feb 1;75(3):555-62
pubmed: 2297567
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
Front Immunol. 2019 Oct 10;10:2361
pubmed: 31649672
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Lancet Haematol. 2015 Mar;2(3):e91-100
pubmed: 26687803
Methods Mol Biol. 2020;2086:139-150
pubmed: 31707673
N Engl J Med. 1957 Sep 12;257(11):491-6
pubmed: 13464965
Cytotherapy. 2016 Aug;18(8):1002-1011
pubmed: 27378344
Front Immunol. 2020 Aug 07;11:1941
pubmed: 32849651